• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors.

作者信息

Ezziddin Samer, Lauschke Holger, Schaefers Michael, Meyer Carsten, van Essen Martijn, Biersack Hans-Jürgen, Kwekkeboom Dik J, Ahmadzadehfar Hojjat

机构信息

Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

出版信息

Clin Nucl Med. 2012 Jan;37(1):102-4. doi: 10.1097/RLU.0b013e318238f111.

DOI:10.1097/RLU.0b013e318238f111
PMID:22157044
Abstract
摘要

相似文献

1
Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors.通过内照射实现新辅助肿瘤缩小：胰腺神经内分泌肿瘤患者术前肽受体放射性核素治疗的病例分析
Clin Nucl Med. 2012 Jan;37(1):102-4. doi: 10.1097/RLU.0b013e318238f111.
2
Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.肽受体放射性核素治疗作为可切除或潜在可切除胰腺神经内分泌肿瘤的新辅助治疗。
Surgery. 2018 Apr;163(4):761-767. doi: 10.1016/j.surg.2017.11.007. Epub 2017 Dec 25.
3
Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.胰高血糖素瘤胰腺神经内分泌肿瘤经 177Lu-DOTATATE 诱导及维持肽受体放射性核素治疗。
Clin Nucl Med. 2015 Nov;40(11):877-9. doi: 10.1097/RLU.0000000000000891.
4
Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.重复肽受体放射治疗转移性神经内分泌肿瘤的多次复发
Nuklearmedizin. 2017 Jun 12;56(3):N19-N21. doi: 10.3413/Nukmed-0863-16-11. Epub 2017 Mar 30.
5
Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor.177Lu-DOTATATE 诱导及维持肽受体放射性核素治疗胰腺神经内分泌肿瘤患者中高肾素血症、继发性醛固酮增多症和低钾血症的缓解。
Clin Nucl Med. 2015 Nov;40(11):880-4. doi: 10.1097/RLU.0000000000000962.
6
Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.胰腺异位促肾上腺皮质激素分泌神经内分泌肿瘤经 177Lu-DOTATATE 诱导及维持肽受体放射性核素治疗。
Clin Nucl Med. 2016 Jan;41(1):50-2. doi: 10.1097/RLU.0000000000000971.
7
[Peptide receptor radionuclide therapy of neuroendocrine tumors].[神经内分泌肿瘤的肽受体放射性核素治疗]
Ugeskr Laeger. 2009 Mar 23;171(13):1073.
8
Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery.转移性胃周神经内分泌癌经“新辅助”肽受体放射性核素治疗和手术治疗后完全缓解。
Clin Nucl Med. 2015 Aug;40(8):667-9. doi: 10.1097/RLU.0000000000000805.
9
Emerging treatment modalities for advanced pancreatic neuroendocrine tumors.晚期胰腺神经内分泌肿瘤的新兴治疗方式。
Hormones (Athens). 2016 Oct;15(4):563-564. doi: 10.14310/horm.2002.1702.
10
Neoadjuvant therapy with peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours.肽受体放射性核素治疗用于胰腺神经内分泌肿瘤的新辅助治疗
Br J Surg. 2024 Aug 30;111(9). doi: 10.1093/bjs/znae183.

引用本文的文献

1
Grade 3 Pancreatic Neuroendocrine Tumor Refractory to Chemotherapy Successfully Treated with Peptide Receptor Radionuclide Therapy Leading to Conversion Surgery.3级胰腺神经内分泌肿瘤对化疗耐药，采用肽受体放射性核素治疗成功，实现了转化手术。
Intern Med. 2025 Mar 1;64(5):679-685. doi: 10.2169/internalmedicine.3768-24. Epub 2024 Jul 25.
2
Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report.胰腺神经内分泌肿瘤切除术后联合肽受体放射性核素治疗和生长抑素类似物实现初始不可切除的多发肝转移灶的病理完全缓解：一例报告
Surg Case Rep. 2024 Feb 14;10(1):40. doi: 10.1186/s40792-024-01839-4.
3
Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.胰腺神经内分泌肿瘤的新辅助治疗：一项系统评价与荟萃分析。
Front Oncol. 2022 Nov 24;12:981575. doi: 10.3389/fonc.2022.981575. eCollection 2022.
4
Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review.放射性配体治疗（RLT）作为不可切除的胰腺神经内分泌肿瘤的新辅助治疗：文献综述。
Endocrine. 2022 Nov;78(2):255-261. doi: 10.1007/s12020-022-03170-0. Epub 2022 Aug 26.
5
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.神经内分泌肿瘤系统治疗的诊断、治疗和反应评估的立场声明，重点关注放射性配体治疗。
Oncologist. 2022 Apr 5;27(4):e328-e339. doi: 10.1093/oncolo/oyab041.
6
Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors.肽受体放射性核素治疗作为原发性不可切除神经内分泌肿瘤新辅助治疗的价值
Front Oncol. 2021 Nov 12;11:687925. doi: 10.3389/fonc.2021.687925. eCollection 2021.
7
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.神经内分泌肿瘤的新辅助治疗：最新进展与未来方法。
Front Endocrinol (Lausanne). 2021 Jul 26;12:651438. doi: 10.3389/fendo.2021.651438. eCollection 2021.
8
Neoadjuvant PRRT for advanced pNEN: an unusual highlander.晚期胰腺神经内分泌肿瘤的新辅助肽受体放射性核素治疗：一个不寻常的“高地人”
Endocrine. 2021 Aug;73(2):493-495. doi: 10.1007/s12020-021-02662-9. Epub 2021 Mar 4.
9
The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.北美神经内分泌肿瘤学会关于胰腺神经内分泌肿瘤手术治疗的共识文件。
Pancreas. 2020 Jan;49(1):1-33. doi: 10.1097/MPA.0000000000001454.
10
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.神经内分泌肿瘤的靶向系统治疗：现有选择与未来展望。
Drugs. 2019 Jan;79(1):21-42. doi: 10.1007/s40265-018-1033-0.